Skip to main content
. Author manuscript; available in PMC: 2015 Sep 18.
Published in final edited form as: AIDS. 2015 Sep 10;29(14):1871–1882. doi: 10.1097/QAD.0000000000000790

Table 4.

Results of the longitudinal analyses focusing on the interaction between the period of combination antiretroviral therapy initiation (2000–2006 and 2007–2012) and CD4+ cell count level at combination antiretroviral therapy initiation (<350 versus ≥350 cells/μl and <500 versus ≥500 cells/μl).

Variable Predicted probability of maintaining adherence ≥95% over time Predicted probability of maintaining viral suppression over time Predicted probability of developing resistance to any drug class over time Predicted probability of developing an AIDS-defining illness by the end of follow-up Predicted probability of being dead by the end of follow-up
Period and CD4+ cell count (cells/μl), median (Q1–Q3)
 2000–2006 and <350 0.79 (0.67–0.86) 0.77 (0.58–0.90) 0.11 (0.07–0.18) 0.14 (0.08–0.22) 0.14 (0.08–0.22)
 2000–2006 and ≥350 0.72 (0.56–0.81) 0.70 (0.45–0.88) 0.04 (0.03–0.08) 0.13 (0.08–0.22) 0.14 (0.09–0.22)
 2007–2012 and <350 0.83 (0.73–0.88) 0.68 (0.57–0.79) 0.05 (0.03–0.08) 0.05 (0.03–0.08) 0.05 (0.03–0.08)
 2007–2012 and ≥350 0.83 (0.74–0.87) 0.68 (0.58–0.77) 0.02 (0.01–0.02) 0.03 (0.01–0.05) 0.02 (0.01–0.04)
Period and CD4+ cell count (cells/μl), median (Q1–Q3)
 2000–2006 and <500 0.75 (0.62–0.84) 0.77 (0.58–0.90) 0.11 (0.07–0.18) 0.04 (0.02–0.08) 0.13 (0.08–0.22)
 2000–2006 and ≥500 0.55 (0.36–0.70) 0.51 (0.23–0.79) 0.04 (0.03–0.08) 0.02 (0.01–0.03) 0.16 (0.10–0.24)
 2007–2012 and <500 0.82 (0.73–0.87) 0.68 (0.58–0.78) 0.04 (0.03–0.07) 0.03 (0.01–0.04) 0.05 (0.03–0.08)
 2007–2012 and ≥500 0.84 (0.75–0.88) 0.65 (0.55–0.74) 0.01 (0.01–0.02) 0.01 (0.00–0.01) 0.01 (0.01–0.02)

Q1: 25th percentile, Q3: 75th percentile. Models were adjusted for predicted probability of maintaining adherence ≥95% over time (for both CD4+ cell count cut-offs) – age, sex, history of injection drug use, longitudinal viral load and follow-up time; predicted probability of maintaining viral suppression over time (for both CD4+ cell count cut-offs) – age, sex, history of injection drug use, longitudinal adherence to cART and follow-up time; predicted probability of developing resistance to any drug class over time (for both CD4+ cell count cut-offs) – age, sex, history of injection drug use, longitudinal adherence to cART, longitudinal viral load and follow-up time; predicted probability of developing an AIDS-defining illness by the end of follow-up (for both CD4+ cell count cut-offs) – history of injection drug use, longitudinal adherence to cART, longitudinal viral load and follow-up time; predicted probability of being dead by the end of follow-up (for both CD4+ cell count cut-offs) – age, sex, history of injection drug use, longitudinal adherence to cART, longitudinal viral load and follow-up time.